COMMUNIQUÉS West-GlobeNewswire

Eurobio Scientific : BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE

17/01/2024 - 17:45

BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE Paris, le 17 janvier 2024 – 17h45 Au titre du contrat de liquidité portant sur les actions de la société EUROBIO SCIENTIFIC (FR0013240934 – ALERS FP) confié à TP ICAP (Europe [...]

VIRBAC: Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%

17/01/2024 - 17:45

KEY FIGURES Annual Revenue 2023 €1,246.9 million Growth at constant exchange rates and scope 1 +4.9% of which companion animals +3.5% farm animals +6.7% Growth at constant exchange rates +4.9% Overall change +2.5% 1 [...]

VIRBAC: Croissance du chiffre d’affaires annuel à +4,9% grâce à un niveau record d’activité au quatrième trimestre à +11,5%

17/01/2024 - 17:45

CHIFFRES CLÉS Chiffre d’affaires annuel 2023 1 246,9 M€ Croissance à taux de change et périmètre constants 1 +4,9% dont animaux de compagnie +3,5% animaux d’élevage +6,7% Croissance à taux de change constants +4,9% [...]

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024

17/01/2024 - 17:00

Postponement of the decision on the adoption of a sale plan ( plan de cession ) and the opening of judicial liquidation proceedings to January 31, 2024 Paris, France, January 17, 202 4 – 5:00 pm (CET) – Pixium Vision SA [...]

Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024

17/01/2024 - 17:00

Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024 Paris, France, 17 janvier 2024 – 17h00 CET – Pixium Vision SA (Euronext Growth [...]

Zealand Pharma major shareholder announcement: J O Hambro Capital Management

17/01/2024 - 16:30

Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78 [...]

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

17/01/2024 - 16:30

First order for IV-Cell placed by Major Japanese Laboratory NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an [...]

The Emily Program Announces Residential Treatment Expansion to Adults in Columbus, Ohio

17/01/2024 - 15:27

With the addition of adult residential treatment in Columbus, the eating disorder program will offer all levels of care to people of all ages and genders in Central Ohio COLUMBUS, Ohio, Jan. 17, 2024 (GLOBE NEWSWIRE [...]

Trxade health, Inc files its 3Q 10Q

17/01/2024 - 15:07

TAMPA, FL, Jan. 17, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of pharmaceutical business-to-business exchange platform, announced today that it filed its Quarterly Report [...]

Sienna Announces Fourth Quarter 2023 Results Release Date and Conference Call

17/01/2024 - 15:00

MARKHAM, Ontario, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2023 fourth quarter results after market close on Tuesday, [...]

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

17/01/2024 - 14:34

TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome [...]

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

17/01/2024 - 14:30

AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell responses that correlated with [...]

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

17/01/2024 - 14:30

Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory Biomarkers [...]

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

17/01/2024 - 14:00

INVO (NASDAQ: INVO ) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneurial leadership team to help structure merged public company and [...]

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

17/01/2024 - 14:00

Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE [...]

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

17/01/2024 - 14:00

Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newborns SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( [...]

Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

17/01/2024 - 14:00

Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for products in the [...]

Day One Announces Two New Appointments to Board of Directors

17/01/2024 - 14:00

BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted [...]

Safety Shot Responds to FSD Pharma’s 3rd unauthorized Tagging of its Stock and Making False Claims in an Effort to Harm the Company and its Shareholders

17/01/2024 - 14:00

Safety Shot is Not GBB Drink Lab, Inc. (GBB) and never acquired GBB as falsely claimed by FSD Pharma; Only the Safety Shot beverage asset was acquired; The lawsuit referred to by FSD Pharma is with GBB only GBB [...]